World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
65
Citations
23018
World Ranking
8974
National Ranking
3987

Overview

Jason J. Luke is affiliated with the University of Pittsburgh in the United States. Their research predominantly spans the fields of Medicine and Immunology and Microbiology, with a focus on Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine, and Cancer Research as key subfields.

The main topics covered in their work include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cutaneous Melanoma Detection and Management
  • Melanoma and MAPK Pathways
  • Cancer Research and Treatments
  • Interferon and immune responses

Jason J. Luke has contributed extensively to academic literature, with frequent publications appearing in these venues:

  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research

Some of their recent papers include:

  • Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study, 2024, The Lancet
  • Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma, 2020, Cancer Cell
  • STING Agonists as Cancer Therapeutics, 2021, Cancers
  • Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas, 2021, Clinical Cancer Research
  • Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma, 2021, Journal of Clinical Oncology

Jason J. Luke frequently collaborates with several co-authors, including:

  • Riyue Bao
  • Diwakar Davar
  • John M. Kirkwood
  • Georgina V. Long
  • Yana G. Najjar

Best Publications

  • The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

    Vyara Matson;Jessica Fessler;Riyue Bao;Tara Chongsuwat

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • Targeted agents and immunotherapies: optimizing outcomes in melanoma.

    Jason J. Luke;Keith T. Flaherty;Antoni Ribas;Georgina V. Long;Georgina V. Long

  • Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

    Christophe Massard;Michael S. Gordon;Sunil Sharma;Saeed Rafii

  • Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA

    Geoffrey R Oxnard;Cloud P Paweletz;Yanan Kuang;Stacy L Mach

  • WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers

    Jason J. Luke;Riyue Bao;Randy F. Sweis;Stefani Spranger

  • Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

    F. Stephen Hodi;Christopher L. Corless;Anita Giobbie-Hurder;Jonathan A. Fletcher

  • Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

    Jason J. Luke;Jeffrey M. Lemons;Theodore G. Karrison;Sean P. Pitroda

  • Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

    Lucie Heinzerling;Patrick A. Ott;F. Stephen Hodi;Aliya N. Husain

  • Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.

    Stefani Spranger;Jason J Luke;Riyue Bao;Yuanyuan Zha

  • Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

    Catherine S. Grasso;Catherine S. Grasso;Jennifer Tsoi;Mykola Onyshchenko;Gabriel Abril-Rodriguez

  • STING Agonists as Cancer Therapeutics.

    Afsaneh Amouzegar;Manoj Chelvanambi;Jessica N. Filderman;Walter J. Storkus

  • T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection

    Jonathan A. Trujillo;Randy F. Sweis;Riyue Bao;Jason J. Luke

  • Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

    Tara C Mitchell;Omid Hamid;David C Smith;Todd M Bauer

  • Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis

    Brian W. Labadie;Riyue Bao;Jason J. Luke

  • STING pathway agonism as a cancer therapeutic.

    Blake A. Flood;Emily F. Higgs;Shuyin Li;Jason J. Luke

  • The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

    Alexander N. Shoushtari;Alexander N. Shoushtari;Rodrigo R. Munhoz;Deborah Kuk;Patrick A. Ott

  • Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study

    Le Min;Frank Stephen Hodi;Anita Giobbie-Hurder;Patrick A. Ott

  • Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

    Lawrence Fong;Andrew Hotson;John D. Powderly;Mario Sznol

  • Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

    Jason J. Luke;Margaret K. Callahan;Michael A. Postow;Emanuela Romano

Frequent Co-Authors

Thomas F. Gajewski
Thomas F. Gajewski University of Chicago
F. Stephen Hodi
F. Stephen Hodi Harvard University
Patrick A. Ott
Patrick A. Ott Harvard University
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Michael A. Postow
Michael A. Postow Memorial Sloan Kettering Cancer Center
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Douglas B. Johnson
Douglas B. Johnson Vanderbilt University Medical Center
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute
Jedd D. Wolchok
Jedd D. Wolchok Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

A background in Biology or Biochemistry opens doors to several high-demand careers in healthcare and science. Many students pursue online programs for flexibility and accessibility. For example, those interested in diagnostic imaging can enroll in ultrasound tech programs online to train for roles as sonographers.

Another rewarding field is radiology. Students looking for entry-level opportunities can start with online radiology programs, which often offer affordable pathways to becoming a radiologic technologist.

For those passionate about nutrition and wellness, earning an advanced degree at one of the best schools for masters in nutrition can lead to fulfilling roles as registered dietitians or nutrition consultants.

Finally, aspiring healthcare professionals can consider online medical assistant programs with financial aid, which combine comprehensive training with financial support options.

Exploring these online degrees can help you find a pathway that complements your interests in Biology and Biochemistry, while offering flexibility for your individual needs.

Best Scientists Citing Jason J. Luke

Trending Scientists

Recently Published Articles